Europe pharmaceutical manufacturing industry accounted for $84.31 billion in 2020 and will grow by 12.9% annually over 2020-2030 driven by increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, and increasing per capita healthcare expenditure amid the COVID-19 pandemic.
Highlighted with 36 tables and 64 figures, this 131-page report "Europe Pharmaceutical Manufacturing Industry 2020-2027 by Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity" is based on a comprehensive research of the entire Europe pharmaceutical manufacturing industry and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate/forecast from 2020 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
- Industry Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Industry Opportunities
- Porter's Fiver Forces
The trend and outlook of Europe industry is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe pharmaceutical manufacturing industry in every aspect of the classification from perspectives of Formulation, Route of Administration, Age Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.
Based on Formulation, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Tablets
- Capsules
- Injectable
- Sprays
- Suspensions
- Powders
- Other Formulations
Based on Route of Administration, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Oral Medicine
- Topical Medicine
- Parenteral Medicine
- Inhalations
- Other Routes of Administration
Based on Age Group, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Children & Adolescents
- Adults
- Geriatric
Based on Therapeutic Application, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Cardiovascular Diseases
- Pain
- Diabetes
- Cancer
- Respiratory Diseases
- Neurological Diseases
- Orthopedics
- Other Applications
Based on Drug Type, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Branded Prescription Drugs
- Generic Prescription Drugs
- OTC Drugs
Based on Distribution Channels, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- Retail Channels
- Non-retail Channels
Based on Manufacturing Facility, the Europe industry is segmented into the following sub-markets with annual production value for 2017-2027 included in each section.
- In-house Facility
- Outsourced Facility
Geographically, the following national/local markets are fully investigated:
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Rest of Europe (further segmented into Netherlands, Switzerland, Turkey, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual production value are available for 2017-2027. The breakdown of key national industry by Formulation, Route of Administration, and Drug Type over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including industry leaders and important emerging players.
Specifically, potential risks associated with investing in Europe pharmaceutical manufacturing industry are assayed quantitatively and qualitatively through GMD's Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Aenova Group
Amgen
AstraZeneca
Catalent Inc.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences
GlaxoSmithKline plc
Johnson & Johnson
Lonza Group
Lupin
Merck & Co., Inc.
Novartis AG
Novo Nordisk
Pfizer, Inc.
Roche
Sanofi SA
Takeda
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
